Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE7A | Q13946 | 2/20 | 0.33 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.31 |
| ▸ | ABL1 | P00519 | 1/20 | 0.30 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3403468 | 0.88 | PDE7A (0.40) | PDE7ARCE1ABL1RIN1 | |
| SCHEMBL719715 | 0.79 | HTR3A (0.37) | PDE7ARCE1ABL1RIN1 | |
| SCHEMBL720161 | 0.79 | P2RX7 (0.38) | PDE7ARCE1ABL1RIN1 | |
| SCHEMBL721466 | 0.76 | PDE7A (0.36) | PDE7ARCE1ABL1RIN1 | |
| SCHEMBL717433 | 0.75 | GCG (0.47) | PDE7A | |
| SCHEMBL718836 | 0.73 | GCG (0.39) | — | |
| SCHEMBL721467 | 0.71 | SSTR4 (0.35) | PDE7ARCE1ABL1RIN1 | |
| SCHEMBL718677 | 0.69 | GCG (0.34) | — | |
| SCHEMBL718414 | 0.67 | GCG (0.43) | RCE1ABL1RIN1 | |
| SCHEMBL718994 | 0.67 | RCE1 (0.38) | RCE1ABL1RIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120053173-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053173-A1 | HETEROCYCLIC COMPOUND | SLC5A2, SLC5A1, IAPP | PDE7A 2449/4885RCE1 2661/4885ABL1 2349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.